|Table of Contents|

Prognostic value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio before treatment in extranodal NK/T-cell lymphoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 07
Page:
1299-1304
Research Field:
Publishing date:

Info

Title:
Prognostic value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio before treatment in extranodal NK/T-cell lymphoma
Author(s):
SHI Shuling1; WANG Yingyi1; WU Jingjing1; LIANG Tiansong1; 2; ZHENG Yingjuan1; 2; YANG Daoke1; 2
1.Radiotherapy Department，the First Affiliated Hospital of Zhengzhou University，Henan Zhengzhou 450000，China;2 Institute of Ｒadiation Therapy and Oncology Emergency Critical Care，Zhengzhou University，Henan Zhengzhou 450000，China．
Keywords:
extranodal natural killer/T-cell lymphoma; neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; prognosis
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2024.07.020
Abstract:
Objective:To investigate the prognostic value of pretreatment neutrophil-lymphocyte ratio(NLR) and platelet-lymphocyte ratio(PLR) in patients with extranodal NK/T-cell lymphoma(ENKTL).Methods:The clinical data of newly diagnosed ENKTL patients in our hospital between January 2012 to December 2016 were retrospectively analyzed.The optimal cut-off values of NLR and PLR were calculated according to the receiver operating characteristic(ROC) curve,after which the patients were grouped.Differences in clinical characteristics and the short-term efficacy of treatment between the groups were analyzed using 2 or Fisher's exact tests.Univariate and multivariate survival analyses were performed using the Cox proportional hazards model to identify the risk factors affecting prognosis.The survival curves were drawn by the Kaplan-Meier method,and log-rank tests were used to compare the differences between the survival curves of each group.P＜0.05 was considered statistically significant.Results:The optimal cut-off values for NLR and PLR were 2.62 and 228.8,respectively.Pretreatment PLR and NLR are correlated with B symptoms and EBV DNA copy number(P＜0.05).There were no statistically significant differences in the short-term efficacy of treatment in the different NLR and PLR groups.Univariate and multivariate analysis showed that NLR(P=0.009),PLR(P=0.008) and LDH(P=0.019) were independent risk factors for overall survival in ENKTL patients.Patients with high NLR or high PLR had lower OS rates(P＜0.001).Conclusion:Pretreatment NLR and PLR can be used as independent prognostic factors for patients with extranodal NK/T lymphoma,and high NLR and high NLR indicate poor prognosis.

References:

[1]LIMA M.Aggressive mature natural killer cell neoplasms:from epidemiology to diagnosis ［J］.Orphanet Journal of Rare Diseases,2013,8:95.
[2]HAVERKOS BM,PAN Z,GRU AA,et al.Extranodal NK/T cell lymphoma,nasal type(ENKTL-NT):An update on epidemiology,clinical presentation,and natural history in North American and European cases ［J］.Curr Hematol Malig Rep,2016,11(6):514-527.
[3]DENG XW,WU JX,WU T,et al.Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma:A multicenter study from the China Lymphoma Collaborative Group(CLCG) ［J］.Radiother Oncol,2018,129(1):3-9.
[4]EGASHIRA M,KAWAMATA N,SUGIMOTO K,et al.P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue,PSC833 ［J］.Blood,1999,93(2):599-606.
[5]WANG X,HU J,DONG M,et al.DDGP vs.SMILE in relapsed/refractory extranodal natural killer/T-cell lymphoma,nasal type:A retrospective study of 54 patients ［J］.Clin Transl Sci,2021,14(1):405-411.
[6]CHEN SY,YANG Y,QI SN,et al.Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era:indication for prognostication and clinical decision-making ［J］.Leukemia,2021,35(1):130-142.
[7]KANAKRY JA,HEGDE AM,DURAND CM,et al.The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases ［J］.Blood,2016,127(16):2007-2017.
[8]LIM SH,HONG JY,LIM ST,et al.Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma:clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease ［J］.Ann Oncol,2017,28(9):2199-2205.
[9]YOO C,YOON DH,JO JC,et al.Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma ［J］.Ann Hematol,2014,93(6):995-1000.
[10] SENGA SS,GROSE RP.Hallmarks of cancer-the new testament ［J］.Open Biology,2021,11(1):200358.
[11] CUPP MA,CARIOLOU M,TZOULAKI I,et al.Neutrophil to lymphocyte ratio and cancer prognosis:an umbrella review of systematic reviews and meta-analyses of observational studies ［J］.BMC Med,2020,18(1):360.
[12] ZHOU X,DU Y,HUANG Z,et al.Prognostic value of PLR in various cancers:a meta-analysis ［J］.PLoS One,2014,9(6):e101119.
[13] AU WY,WEISENBURGER DD,INTRAGUMTORNCHAI T,et al.Clinical differences between nasal and extranasal natural killer/T-cell lymphoma:a study of 136 cases from the international peripheral T-cell lymphoma project ［J］.Blood,2009,113(17):3931-3937.
[14] HANAHAN D.Hallmarks of cancer:New dimensions ［J］.Cancer Discovery,2022,12(1):31-46.
[15] 叶德宇,杨帅,赵龙龙,等.炎性标志物对恶性肿瘤发生发展和预后的影响及其机制的研究进展 ［J］.吉林大学学报(医学版)，2022,48(04):1079-1087. YE DY,YANG S,ZHAO LL,et al.Research progress in effects of inflammatory markers on occurrence,development and prognosis of malignant tumors and their mechanisms［J］.Journal of Jilin University (Medicine Edition),2022,48(04):1079-1087.
[16] WOUTERS MCA,NELSON BH.Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer ［J］.Clin Cancer Res,2018,24(24):6125-6135.
[17] HU X,TIAN T,ZHANG X,et al.Neutrophil-to-lymphocyte and hypopharyngeal cancer prognosis:System review and meta-analysis［J］.Head & Neck,2023,45(2):492-502.
[18] TAN KM,CHIA B,LIM JQ,et al.A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma:A multicenter study ［J］.Sci Rep,2019,9(1):14961.
[19] HUANG H,CHEN LM,FANG XJ,et al.Prognostic value of the modified systemic inflammation score in patients with extranodal natural killer/T-cell lymphoma ［J］.Frontiers in Pharmacology,2020,11:593392.
[20] LABELLE M,BEGUM S,HYNES RO.Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis ［J］.Cancer Cell,2011,20(5):576-590.
[21] BARANYAI Z,JOSA V,TOTH A,et al.Paraneoplastic thrombocytosis in gastrointestinal cancer ［J］.Platelets,2016,27(4):269-275.
[22] ZHOU H,LI J,ZHANG Y,et al.Platelet-lymphocyte ratio is a prognostic marker in small cell lung cancer-A systemic review and meta-analysis［J］.Frontiers in Oncology,2022,12:1086742.
[23] ZHANG J,FENG W,YE Z,et al.Prognostic significance of platelet-to-lymphocyte ratio in patients with nasopharyngeal carcinoma:a meta-analysis ［J］.Future Oncology(London,England),2020,16(5):117-127.
[24] CHEN Y,ZHANG Z,FANG Q,et al.Prognostic impact of platelet-to-lymphocyte ratio on diffuse large B-cell lymphoma:a meta-analysis ［J］.Cancer Cell Int,2019,19:245.
[25] 权小英,李力,任苑蓉,等.血小板与淋巴细胞比值在早期结NK/T细胞淋巴瘤中的预后价值 ［J］ .肿瘤预防与治疗，2018,31(02):92-98. QUAN XY,LI L,REN WR,et al.The prognostic value of platelet to lymphocyte ratio for early stage extranodal natural killer/T-cell lymphoma ［J］.J Cancer Control Treat,2018,31(02):92-98.
[26] WANG X,WEN L,LIAO J,et al.First-line immunotherapy with anti-PD-1 antibody for extranodal NK/T-cell lymphoma:A retrospective study［J］.British Journal of Haematology,2023,202(4):812-824.
[27] 陈林会,李冰妍,梁天嵩,等.放化疗联合程序性死亡受体1抗体治疗中晚期NK/T细胞淋巴瘤的疗效分析 ［J］ .肿瘤基础与临床，2021,34(03):215-218. CHEN LH,LI BY,LIANG TS,et al.Efficacy of chemoradiotherapy combined with programmed death receptor 1 antibody in the treatment of advanced NK/T cell lymphoma ［J］.Basic and Clinical Oncology,2021,34(03):215-218.
[28] 魏熙胤,张翠翠,臧凤琳,等.炎性指标对非小细胞肺癌PD-1抗体疗效预测及预后评估的初步探讨 ［J］. 中国肿瘤临床，2021,48(11):547-552. WEI XY,ZHANG CC,ZANG FL,et al.Preliminary study on inflammatory markers for predicting the efficacy and prognosis of anti-PD-1 antibody treatment in patients with non-small cell lung cancer［J］.Chin J Clin Oncol,2021,48(11):547-552.

Memo

Memo:
河南省高等学校重点项目科研计划(编号：21A310021)
Last Update: 2024-02-29